Literature DB >> 16804977

Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer.

Luis C Fernandes1, Su B Kim, Sarhan S Saad, Delcio Matos.   

Abstract

AIM: To evaluate the efficacy of postoperative serial assay of carcinoembryonic antigen (CEA) and cytokeratins for the detection of recurrent disease in patients with colorectal adenocarcinoma after radical surgery.
METHODS: Between 1993 and 2000, 120 patients with colorectal adenocarcinoma underwent radical surgery in the Department of Surgical Gastroenterology, Federal University of Sao Paulo-Escola Paulista de Medicina, Sao Paulo, Brazil. Periodic postoperative evaluation was performed by assaying markers in peripheral serum, colonoscopy and imaging examination. Presence of CEA was detected using the Delfia method with 5 microg/L threshold, and cytokeratins using the LIA-mat TPA-M Prolifigen method with 72 U/L threshold.
RESULTS: In the first postoperative year, patients without recurrent disease had normal levels of CEA (1.5 +/- 0.9 microg/L) and monoclonal tissue polypeptide antigen-M (TPA-M, 64.4 +/- 47.8 U/L), while patients with recurrences had high levels of CEA (6.9 +/- 9.8 microg/L, P < 0.01) and TPA-M (192.2 +/- 328.8 U/L, P < 0.05). During the second postoperative year, patients without tumor recurrence had normal levels of CEA (2.0 +/- 1.8 microg/L) and TPA-M (50.8 +/- 38.4 U/L), while patients with recurrence had high levels of CEA (66.3 +/- 130.8 microg/L, P < 0.01) and TPA-M (442.7 +/- 652.8 U/L, P < 0.05). The mean follow-up time was 22.3 mo. There was recurrence in 23 cases. Five reoperations were performed without achieving radical excision. Rises in tumor marker levels preceded identification of recurrences: CEA in seven (30%) and TPA-M in eleven individuals (48%).
CONCLUSION: Intensive follow-up by serial assay of CEA and cytokeratins allows early detection of colorectal neoplasm recurrence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16804977      PMCID: PMC4087940          DOI: 10.3748/wjg.v12.i24.3891

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

1.  Is intensive follow-up really able to improve prognosis of patients with local recurrence after curative surgery for rectal cancer?

Authors:  G B Secco; R Fardelli; S Rovida; D Gianquinto; E Baldi; P Bonfante; L Derchi; R Ferraris
Journal:  Ann Surg Oncol       Date:  2000 Jan-Feb       Impact factor: 5.344

2.  Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma.

Authors:  N Panza; G Pacilio; L Campanella; G Peluso; C Battista; A Amoriello; W Utech; C Vacca; G Lombardi
Journal:  Cancer       Date:  1988-01-01       Impact factor: 6.860

3.  High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of a five-year study.

Authors:  S Wiratkapun; M Kraemer; F Seow-Choen; Y H Ho; K W Eu
Journal:  Dis Colon Rectum       Date:  2001-02       Impact factor: 4.585

4.  Dukes' classification revisited. Findings from the National Surgical Adjuvant Breast and Bowel Projects (Protocol R-01).

Authors:  E R Fisher; R Sass; A Palekar; B Fisher; N Wolmark
Journal:  Cancer       Date:  1989-12-01       Impact factor: 6.860

5.  Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis.

Authors:  J S Gronowitz; R Bergström; E Nôu; S Påhlman; O Brodin; S Nilsson; C F Källander
Journal:  Cancer       Date:  1990-08-15       Impact factor: 6.860

6.  Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study.

Authors:  J P Minton; J L Hoehn; D M Gerber; J S Horsley; D P Connolly; F Salwan; W S Fletcher; A B Cruz; F G Gatchell; M Oviedo
Journal:  Cancer       Date:  1985-03-15       Impact factor: 6.860

7.  Specificity and basis of the tissue polypeptide antigen.

Authors:  B Björklund; V Björklund
Journal:  Cancer Detect Prev       Date:  1983

8.  Relationship between serum calcium and CA 19-9 levels in colorectal cancer.

Authors:  Peter Fuszek; Peter Lakatos; Adam Tabak; Janos Papp; Zsolt Nagy; Istvan Takacs; Henrik Csaba Horvath; Peter Laszlo Lakatos; Gabor Speer
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

9.  Tissue polypeptide antigen (TPA) as a prognostic aid in human prostatic carcinoma.

Authors:  A Lewenhaupt; P Ekman; P Eneroth; B Nilsson; L Nordström
Journal:  Prostate       Date:  1985       Impact factor: 4.104

10.  Assessment of the value of preoperative serum levels of CA 242 and CEA in the staging and postoperative survival of colorectal adenocarcinoma patients.

Authors:  S B Kim; L C Fernandes; S S Saad; D Matos
Journal:  Int J Biol Markers       Date:  2003 Jul-Sep       Impact factor: 3.248

View more
  12 in total

1.  (18)F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer.

Authors:  Long-Bang Chen; Jin-Long Tong; Hai-Zhu Song; Hong Zhu; Yu-Cai Wang
Journal:  World J Gastroenterol       Date:  2007-10-07       Impact factor: 5.742

2.  Accuracy of monitoring serum carcinoembryonic antigen levels in postoperative stage III colorectal cancer patients is limited to only the first postoperative year.

Authors:  Masayasu Hara; Mikinori Sato; Hiroki Takahashi; Satoru Takayama; Hiromitsu Takeyama
Journal:  Surg Today       Date:  2011-09-16       Impact factor: 2.549

3.  Value of Surveillance (18)F-FDG PET/CT in Colorectal Cancer: Comparison with Conventional Imaging Studies.

Authors:  Eun Kyoung Choi; Ie Ryung Yoo; Hye Lim Park; Hyun Su Choi; Eun Ji Han; Sung Hoon Kim; Soo Kyo Chung; Joo Hyun O
Journal:  Nucl Med Mol Imaging       Date:  2012-06-16

4.  Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT.

Authors:  Kazuhiro Kitajima; Koji Murakami; Erena Yamasaki; Yasushi Domeki; Masahiro Tsubaki; Masakatsu Sunagawa; Yasushi Kaji; Narufumi Suganuma; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-16       Impact factor: 9.236

5.  Peripheral and mesenteric serum levels of CEA and cytokeratins, staging and histopathological variables in colorectal adenocarcinoma.

Authors:  Ivan-Gregorio Ivankovics; Luis-Cesar Fernandes; Sarhan-Sydeney Saad; Delcio Matos
Journal:  World J Gastroenterol       Date:  2008-11-21       Impact factor: 5.742

6.  Establishment and characterization of a cell line (OMC-9) originating from a human endometrial stromal sarcoma.

Authors:  Yoshiteru Kakuno; Takashi Yamada; Hiroshi Mori; Isamu Narabayashi
Journal:  Hum Cell       Date:  2008-05       Impact factor: 4.174

7.  Vascular endothelial growth factor levels in ascites between chemonaive and chemotreated patients.

Authors:  Hae Kyung Lee; Hiun Suk Chae; Jin Soo Kim; Hyung Keun Kim; Young Seok Cho; Sang Young Rho; Jin-Hyoung Kang; Seok Goo Cho; Hong Seok Jang; Kyungja Han
Journal:  Yonsei Med J       Date:  2008-06-30       Impact factor: 2.759

Review 8.  Blood CEA levels for detecting recurrent colorectal cancer.

Authors:  Brian D Nicholson; Bethany Shinkins; Indika Pathiraja; Nia W Roberts; Tim J James; Susan Mallett; Rafael Perera; John N Primrose; David Mant
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10

9.  Diagnostic Accuracy of Elevated Serum Carcinoembryonic Antigen for Recurrence in Postoperative Stage II Colorectal Cancer Patients: Comparison With Stage III.

Authors:  Ho Seung Kim; Min Ro Lee
Journal:  Ann Coloproctol       Date:  2013-08-29

10.  The Role of High Frequency Dynamic Threshold (HiDT) Serum Carcinoembryonic Antigen (CEA) Measurements in Colorectal Cancer Surveillance: A (Revisited) Hypothesis Paper.

Authors:  Irene Grossmann; Charlotte Verberne; Geertruida De Bock; Klaas Havenga; Ido Kema; Joost Klaase; Andrew Renehan; Theo Wiggers
Journal:  Cancers (Basel)       Date:  2011-05-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.